Cargando…
The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973542/ https://www.ncbi.nlm.nih.gov/pubmed/33737565 http://dx.doi.org/10.1038/s41598-021-85510-0 |
_version_ | 1783666863216001024 |
---|---|
author | Bakeberg, Megan C. Hoes, Madison E. Gorecki, Anastazja M. Theunissen, Frances Pfaff, Abigail L. Kenna, Jade E. Plunkett, Kai Kõks, Sulev Akkari, P. Anthony Mastaglia, Frank L. Anderton, Ryan S. |
author_facet | Bakeberg, Megan C. Hoes, Madison E. Gorecki, Anastazja M. Theunissen, Frances Pfaff, Abigail L. Kenna, Jade E. Plunkett, Kai Kõks, Sulev Akkari, P. Anthony Mastaglia, Frank L. Anderton, Ryan S. |
author_sort | Bakeberg, Megan C. |
collection | PubMed |
description | Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ allele length was determined in 634 people with PD and 422 healthy controls from an Australian cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that it may be a modifying factor for age of symptom onset warrants further investigation in other PD populations. |
format | Online Article Text |
id | pubmed-7973542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79735422021-03-19 The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease Bakeberg, Megan C. Hoes, Madison E. Gorecki, Anastazja M. Theunissen, Frances Pfaff, Abigail L. Kenna, Jade E. Plunkett, Kai Kõks, Sulev Akkari, P. Anthony Mastaglia, Frank L. Anderton, Ryan S. Sci Rep Article Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ allele length was determined in 634 people with PD and 422 healthy controls from an Australian cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that it may be a modifying factor for age of symptom onset warrants further investigation in other PD populations. Nature Publishing Group UK 2021-03-18 /pmc/articles/PMC7973542/ /pubmed/33737565 http://dx.doi.org/10.1038/s41598-021-85510-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bakeberg, Megan C. Hoes, Madison E. Gorecki, Anastazja M. Theunissen, Frances Pfaff, Abigail L. Kenna, Jade E. Plunkett, Kai Kõks, Sulev Akkari, P. Anthony Mastaglia, Frank L. Anderton, Ryan S. The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title | The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title_full | The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title_fullStr | The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title_full_unstemmed | The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title_short | The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease |
title_sort | tomm40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973542/ https://www.ncbi.nlm.nih.gov/pubmed/33737565 http://dx.doi.org/10.1038/s41598-021-85510-0 |
work_keys_str_mv | AT bakebergmeganc thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT hoesmadisone thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT goreckianastazjam thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT theunissenfrances thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT pfaffabigaill thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT kennajadee thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT plunkettkai thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT kokssulev thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT akkaripanthony thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT mastagliafrankl thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT andertonryans thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT bakebergmeganc tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT hoesmadisone tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT goreckianastazjam tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT theunissenfrances tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT pfaffabigaill tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT kennajadee tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT plunkettkai tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT kokssulev tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT akkaripanthony tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT mastagliafrankl tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease AT andertonryans tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease |